3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 4
2
Phase NA
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Waldenstrom Macroglobulinemia
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pain, Postoperative
1
Ovarian Neoplasms
1
Neuralgia
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Carboplatin
46
Paclitaxel
31
pembrolizumab
25
Cyclophosphamide
24
Nivolumab
14
Bevacizumab
14
Topotecan
12
Gemcitabine
12
liposomal doxorubicin
11
Filgrastim
11
Cisplatin
11
fludarabine
10
Peripheral Blood Stem Cell Transplantation
10
olaparib
8
aldesleukin
7
durvalumab
6
Oxaliplatin
6
Ipilimumab
6
Interleukin-2
6
Docetaxel
6
niraparib
5
epacadostat
5
cemiplimab
5
Ifosfamide
5
Fulvestrant
5
rucaparib
4
poly ICLC
4
pazopanib
4
avelumab
4
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Ovarian Neoplasms
×
Saline Solution
×
Clear all
NCT06888921
2026-04-01
MAIA-ovarian
Compugen Ltd
Phase 1/2
Recruiting
60 enrolled